Objective
The treatment of sickle cell anaemia and ß thalassaemia is at present inadequate, expensive and unsatisfactory. There is an urgent need for novel treatments and two possibilities can be envisioned. Firstly the treatment with small molecules that interfere with the transcription process and may reactivate the y-globin genes which are normally suppressed in adults. This approach is the subject of this proposal. The second possibility would be gene therapy, which is the subject of another proposal. Here we propose to make mouse models which can be used to screen and test compounds that interfere with y globin gene suppression and to study factors that are important in the switching from y to ß globin genes. The identification of such factors may provide a rational approach to design molecules that interfere with y and ß globin gene expression.
The objectives are:
1. The generation of transgenic mice which model human thalassaemia and sickle cell anaemia.
2. The generation of transgenic mice which carry a complete human ß-globin gene domain in which one of the foetal globin genes expresses luciferase. 3. The generation of erythroid cell lines from the luciferase mice (2 above) by infection with Friend virus or crossing with transgenic mice that carry a GATA-T antigen construct (Ottolenghi). These cell lines will be used in a robotic screen for novel therapeutic compounds that can activate y globin gene expression in the adult.
4. The testing of candidate therapeutic compounds in transgenic mice and human erythroid cell cultures.
5. The identification of transcription elements and their cognate transcription factors important for y globin gene activation/suppression and the switch to ß globin expression.
Keywords: Haemoglobinopathies, drug discovery, transcriptional regulation, transgenic mouse models.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences basic medicine pharmacology and pharmacy drug discovery
- medical and health sciences medical biotechnology genetic engineering gene therapy
- natural sciences biological sciences microbiology virology
You need to log in or register to use this function
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Data not available
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
3000 DR Rotterdam
Netherlands
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.